-
New Research Presented at AACE & ITC
The Afirma Team
August 8, 2025
-
Afirma® GSC Benign Results Demonstrate Real-World Utility in Outcomes Study
The Afirma Team
June 12, 2025
-
Confidently Rule Out Thyroid Cancer in Your Clinic With an Afirma® GSC Benign Result
The Afirma Team
April 23, 2025
-
New Research from Veracyte Examines the Landscape of BRAF Fusions in Thyroid Tumors
Joshua Klopper, MD
April 4, 2025
-
The Tumor Microenvironment
Joshua Klopper, MD
February 4, 2025
-
New Research Presented at ATA 2024
Joshua Klopper, MD
December 17, 2024
-
Patient Report – BRAF, RAS, Non-BRAF, Non-RAS
Joshua Klopper, MD
October 28, 2024
-
Fresh FNA Sample vs. Slide Scraping
Joshua Klopper, MD
September 31, 2024
-
What is a Whole Transcriptome?
Joshua Klopper, MD
August 16, 2024
-
New Research Presented at ENDO 2024
Joshua Klopper, MD
July 16, 2024
-
New Research Presented at AACE 2024
Joshua Klopper, MD
July 16, 2024
-
The Challenges with Repeat FNA
Joshua Klopper, MD
May 31, 2024
-
Assessing The Data: How Afirma Leverages Literature Reviews
Joshua Klopper, MD
April 29, 2024
-
The Challenge of Oncocytic (Hürthle) Cells
Joshua Klopper, MD
Jan 31, 2024
-
Unlocking the Whole Transcriptome: A Wealth of Information
The Afirma Team
October 23, 2023
-
How TERT and Veracyte’s Afirma GSC Can Help Personalize Treatment Decisions in Thyroid Cancer
Joshua Klopper, MD
May 3, 2023
-
Recent Study Shows That, Yes, We Can Leave More Thyroids Intact
Lindsay Lipe, MS, CGC
Joshua Klopper, MD
July 27, 2022
-
How Does the Afirma Genomic Test Perform in the Real World?
Joshua Klopper, MD
July 27, 2022
